title: Clinical and immunologic effects of monoclonal antibody CC49 and interleukin-2 in patients with metastatic colorectal cancer.
abstract: We examined the possibility that prior exposure to the murine monoclonal antibody (mAb), CC49, which recognizes the pancarcinoma antigen, TAG-72, would modify the clinical activity of interleukin-2 (IL-2) in patients with metastatic colorectal cancer. Fourteen patients received 2 mg of unconjugated CC49 on Day 1; on Day 22, they began human recombinant IL-2 at 1 mg/m2/day for 4 days by continuous IV infusion. Four-day cycles of IL-2 were repeated weekly for 8 weeks unless there was evidence of unacceptable toxicity or progressive disease. Therapy was well tolerated. Proliferative responses of peripheral blood mononuclear cells (PBMC) to CC49, its Fab fragment, isotype matched murine immunoglobulin, and CC49 complexed with TAG-72+ mucin increased after CC49 administration (Day 21). These proliferative responses decreased after IL-2 administration. PBMC proliferative responses to AI49, an anti-CC49 idiotype antibody (Ab2), and TAG-72+ mucin was not induced. No complete or partial clinical responses were observed; one patient manifested a transient mixed response. A single infusion of CC49 does have biologic activity; it is, however, unlikely to substantially modify tumor response rates effected by IL-2 in patients with metastatic colorectal cancer.
authors.affiliation: Arthur G. James Cancer Hospital and Research Institute, Ohio State University Comprehensive Cancer Center, Columbus, USA.
authors.forename: P L
authors.initials: PL
authors.lastname: Triozzi
authors.forename: J A
authors.initials: JA
authors.lastname: Kim
authors.forename: E W
authors.initials: EW
authors.lastname: Martin
authors.forename: D
authors.initials: D
authors.lastname: Colcher
authors.forename: M
authors.initials: M
authors.lastname: Heffelfinger
authors.forename: R
authors.initials: R
authors.lastname: Rucker
mesh_terms: D000328:Adult; D000368:Aged; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006023:Glycoproteins / Q000276:immunology*; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012983:Soft Tissue Neoplasms / Q000556:secondary
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; C091202:B72.3 antibody; D006023:Glycoproteins; D007376:Interleukin-2; C047052:tumor-associated antigen 72